BONE BIOLOGICS CORP (BBLG) Fundamental Analysis & Valuation

NASDAQ:BBLG • US0980706008

Current stock price

1.305 USD
-0.02 (-1.14%)
Last:

This BBLG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BBLG Profitability Analysis

1.1 Basic Checks

  • BBLG had negative earnings in the past year.
  • BBLG had a negative operating cash flow in the past year.
  • BBLG had negative earnings in each of the past 5 years.
  • BBLG had a negative operating cash flow in each of the past 5 years.
BBLG Yearly Net Income VS EBIT VS OCF VS FCFBBLG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • BBLG has a Return On Assets of -53.64%. This is comparable to the rest of the industry: BBLG outperforms 43.88% of its industry peers.
  • With a Return On Equity value of -57.81%, BBLG perfoms like the industry average, outperforming 57.67% of the companies in the same industry.
Industry RankSector Rank
ROA -53.64%
ROE -57.81%
ROIC N/A
ROA(3y)-160.91%
ROA(5y)-104.85%
ROE(3y)-191.99%
ROE(5y)-125.06%
ROIC(3y)N/A
ROIC(5y)N/A
BBLG Yearly ROA, ROE, ROICBBLG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2K -2K -4K -6K -8K -10K

1.3 Margins

  • BBLG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBLG Yearly Profit, Operating, Gross MarginsBBLG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BBLG Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, BBLG has more shares outstanding
  • Compared to 5 years ago, BBLG has more shares outstanding
  • There is no outstanding debt for BBLG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BBLG Yearly Shares OutstandingBBLG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M
BBLG Yearly Total Debt VS Total AssetsBBLG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • BBLG has an Altman-Z score of -18.61. This is a bad value and indicates that BBLG is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -18.61, BBLG is doing worse than 83.11% of the companies in the same industry.
  • There is no outstanding debt for BBLG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.61
ROIC/WACCN/A
WACCN/A
BBLG Yearly LT Debt VS Equity VS FCFBBLG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M -10M

2.3 Liquidity

  • BBLG has a Current Ratio of 13.85. This indicates that BBLG is financially healthy and has no problem in meeting its short term obligations.
  • BBLG has a Current ratio of 13.85. This is amongst the best in the industry. BBLG outperforms 89.13% of its industry peers.
  • BBLG has a Quick Ratio of 13.85. This indicates that BBLG is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 13.85, BBLG belongs to the top of the industry, outperforming 89.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.85
Quick Ratio 13.85
BBLG Yearly Current Assets VS Current LiabilitesBBLG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BBLG Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 87.38% over the past year.
EPS 1Y (TTM)87.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, BBLG will show a very strong growth in Earnings Per Share. The EPS will grow by 24.92% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.64%
EPS Next 2Y24.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BBLG Yearly EPS VS EstimatesBBLG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -200 -400 -600 -800

More info and screens

Find the best growth stocksShow best growing peers

1

4. BBLG Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BBLG. In the last year negative earnings were reported.
  • Also next year BBLG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBLG Price Earnings VS Forward Price EarningsBBLG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBLG Per share dataBBLG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BBLG's earnings are expected to grow with 24.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.92%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BBLG Dividend Analysis

5.1 Amount

  • BBLG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BBLG Fundamentals: All Metrics, Ratios and Statistics

BONE BIOLOGICS CORP

NASDAQ:BBLG (4/29/2026, 8:00:01 PM)

1.305

-0.02 (-1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.66
Industry Growth13.04
Earnings (Last)03-02
Earnings (Next)05-11
Inst Owners3.29%
Inst Owner Change0%
Ins Owners0.04%
Ins Owner Change0%
Market Cap2.35M
Revenue(TTM)N/A
Net Income(TTM)-3.11M
Analysts82.86
Price Target22.64 (1634.87%)
Short Float %0.4%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)65.07%
Min EPS beat(2)59.63%
Max EPS beat(2)70.51%
EPS beat(4)3
Avg EPS beat(4)9.99%
Min EPS beat(4)-124.81%
Max EPS beat(4)70.51%
EPS beat(8)6
Avg EPS beat(8)-13.01%
EPS beat(12)9
Avg EPS beat(12)-10.04%
EPS beat(16)13
Avg EPS beat(16)2.97%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.22%
PT rev (3m)-0.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-41.91%
EPS NY rev (3m)-41.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.44
EV/EBITDA N/A
EPS(TTM)-3.76
EYN/A
EPS(NY)-1.97
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS0
BVpS2.99
TBVpS2.99
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -53.64%
ROE -57.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-160.91%
ROA(5y)-104.85%
ROE(3y)-191.99%
ROE(5y)-125.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.85
Quick Ratio 13.85
Altman-Z -18.61
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.2%
EPS Next Y47.64%
EPS Next 2Y24.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.76%
OCF growth 3YN/A
OCF growth 5YN/A

BONE BIOLOGICS CORP / BBLG Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BONE BIOLOGICS CORP?

ChartMill assigns a fundamental rating of 3 / 10 to BBLG.


Can you provide the valuation status for BONE BIOLOGICS CORP?

ChartMill assigns a valuation rating of 1 / 10 to BONE BIOLOGICS CORP (BBLG). This can be considered as Overvalued.


How profitable is BONE BIOLOGICS CORP (BBLG) stock?

BONE BIOLOGICS CORP (BBLG) has a profitability rating of 1 / 10.


Can you provide the financial health for BBLG stock?

The financial health rating of BONE BIOLOGICS CORP (BBLG) is 7 / 10.